IXICO secures medical imaging contract for Huntington’s disease Phase III clinical trial

The contract will involve the collection of magnetic resonance imaging (MRI) data from specialist imaging centres to support the development of a drug

Nerves in the brain
The company will use AI to provide insight into the structure of brain cells and nerves

IXICO PLC (LON:IXI) shares soared higher on Tuesday on news the firm has inked a contract with a top 10 pharmaceutical company to provide imagining services for a Pivotal Phase III clinical trial into Huntington’s disease.

The contract, which is to be delivered over four years and carries a value of £9.1mln, extends the company's relationship with an existing client and is its fourth new contract relating to Huntington’s disease in the current financial year.

READ: IXICO expands contract with biopharmaceutical company

Ixico also expanded its contract with another biopharmaceutical company last month to €1.3mln, which focused on the treatment of another neurodegenerative disease, Alzheimer’s.

Giulio Cerroni, chief executive of IXICO, said the new award, combined with the company’s other contract wins and extensions this year, provided a “strong foundation” for future growth, adding that Huntington’s was an area of “significant unmet medical need” as there are currently no effective marketed treatments.

In mid-morning trading, IXICO was the second biggest London market gainer board, with its shares up 29.1% at 35.50p.

 -- Adds share price --

Quick facts: IXICO PLC

Price: 64 GBX

Market: AIM
Market Cap: £30.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...



IXICO PLC - Proactive One2One Virtual Event

IXICO PLC's Giulio Cerroni speaks to investors at the Proactive One2One Virtual Event. IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

on 10/7/20

2 min read